JP4128872B2 - 癌治療法 - Google Patents

癌治療法 Download PDF

Info

Publication number
JP4128872B2
JP4128872B2 JP2002564006A JP2002564006A JP4128872B2 JP 4128872 B2 JP4128872 B2 JP 4128872B2 JP 2002564006 A JP2002564006 A JP 2002564006A JP 2002564006 A JP2002564006 A JP 2002564006A JP 4128872 B2 JP4128872 B2 JP 4128872B2
Authority
JP
Japan
Prior art keywords
day
compound
paclitaxel
component
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2002564006A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004517961A (ja
JP2004517961A5 (https=
Inventor
ホルジャー ブレイマー，ラース
ディングラ，カピル
ディングラ，ウルバシ，ホーダ
リットランド，スティーブ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2004517961A publication Critical patent/JP2004517961A/ja
Publication of JP2004517961A5 publication Critical patent/JP2004517961A5/ja
Application granted granted Critical
Publication of JP4128872B2 publication Critical patent/JP4128872B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2002564006A 2001-02-09 2002-02-01 癌治療法 Expired - Lifetime JP4128872B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26787401P 2001-02-09 2001-02-09
PCT/EP2002/001042 WO2002064214A2 (en) 2001-02-09 2002-02-01 Anti cancer combination of substituted pyrroles and paclitaxel

Publications (3)

Publication Number Publication Date
JP2004517961A JP2004517961A (ja) 2004-06-17
JP2004517961A5 JP2004517961A5 (https=) 2008-05-08
JP4128872B2 true JP4128872B2 (ja) 2008-07-30

Family

ID=23020488

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002564006A Expired - Lifetime JP4128872B2 (ja) 2001-02-09 2002-02-01 癌治療法

Country Status (17)

Country Link
US (1) US6548531B2 (https=)
EP (1) EP1359979B1 (https=)
JP (1) JP4128872B2 (https=)
KR (1) KR100542069B1 (https=)
CN (1) CN1265786C (https=)
AR (2) AR035429A1 (https=)
AT (1) ATE324145T1 (https=)
AU (1) AU2002246080B2 (https=)
BR (1) BR0206954A (https=)
CA (1) CA2435921C (https=)
DE (1) DE60210926T2 (https=)
DK (1) DK1359979T3 (https=)
ES (1) ES2261648T3 (https=)
MX (1) MXPA03007036A (https=)
PT (1) PT1359979E (https=)
WO (1) WO2002064214A2 (https=)
ZA (1) ZA200305967B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
JP2004532245A (ja) * 2001-05-15 2004-10-21 ページ ダブル フォーク 癌を治療するための生体影響性化合物の標的送達
JP2004537515A (ja) * 2001-05-15 2004-12-16 フォーク ファーマシューティカルス，インク． ウィルス感染症治療用薬物のターゲッティング送達
WO2002102373A1 (en) * 2001-06-15 2002-12-27 F. Hoffmann-La Roche Ag Method for administration of cancer therapeutic
US20030139373A1 (en) * 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
KR20070114753A (ko) * 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP3141245A1 (en) 2010-03-29 2017-03-15 Abraxis BioScience, LLC Methods of treating cancer
MX2012011155A (es) 2010-03-29 2012-12-05 Abraxis Bioscience Llc Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
MX347225B (es) 2010-06-04 2017-04-19 Abraxis Bioscience Llc * Metodos de tratamiento contra el cancer pancreatico.
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
WO2018092020A1 (en) 2016-11-15 2018-05-24 Novartis Ag Dose and regimen for hdm2-p53 interaction inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227850A (en) 1988-02-10 1991-11-26 Hoffmann La Roche Indole substituted pyrrole derivatives; preparatory process and medicaments for use against inflammatory immunological, bronchopulmonary or vascular disorders
US6080777A (en) * 1992-01-31 2000-06-27 The Trustees Of Columbia University In The City Of New York Taxol as a radiation sensitizer
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
CA2140653A1 (en) * 1992-08-12 1994-03-03 Irene Abraham Protein kinase inhibitors and related compounds combined with taxol
PT1064279E (pt) 1998-03-17 2003-10-31 Hoffmann La Roche Bisindolilmaleimidas substituidas para a inibicao da proliferacao celular
WO1999055321A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6277844B1 (en) * 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression

Also Published As

Publication number Publication date
WO2002064214A3 (en) 2003-05-30
AU2002246080C1 (en) 2002-08-28
ZA200305967B (en) 2005-01-26
CN1491126A (zh) 2004-04-21
ATE324145T1 (de) 2006-05-15
DK1359979T3 (da) 2006-08-28
AR098745A2 (es) 2016-06-08
MXPA03007036A (es) 2003-11-18
CN1265786C (zh) 2006-07-26
EP1359979A2 (en) 2003-11-12
PT1359979E (pt) 2006-08-31
WO2002064214A8 (en) 2004-02-19
BR0206954A (pt) 2004-02-25
US20020156118A1 (en) 2002-10-24
JP2004517961A (ja) 2004-06-17
KR20040025894A (ko) 2004-03-26
US6548531B2 (en) 2003-04-15
WO2002064214A2 (en) 2002-08-22
AR035429A1 (es) 2004-05-26
EP1359979B1 (en) 2006-04-26
CA2435921C (en) 2009-12-22
DE60210926D1 (de) 2006-06-01
ES2261648T3 (es) 2006-11-16
AU2002246080B2 (en) 2006-08-10
CA2435921A1 (en) 2002-08-22
KR100542069B1 (ko) 2006-01-11
DE60210926T2 (de) 2007-01-11

Similar Documents

Publication Publication Date Title
Gaynon et al. Carboplatin in childhood brain tumors: a Children's Cancer Study Group phase II trial
Vokes et al. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
JP4128872B2 (ja) 癌治療法
AU2002246080A1 (en) Method for Cancer Therapy
US4384001A (en) Treatment of tumors with thiazolidine-4-carboxylic acid
ES2241639T3 (es) Terapia de combinacion que usa un compuesto de pentafluorobencensulfonamidas y platino.
Harvey et al. Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer
JP5317987B2 (ja) 白血病の治療のための新規な治療のための使用
JPH1045589A (ja) テモゾロミドによる改良されたガンの処置
RU2284818C2 (ru) Комбинированная химиотерапия
South-East European Oncology Group (SEEOG) et al. Phase II study of 4′-epi-doxorubicin in patients with untreated, extensive small cell lung cancer
CN111407748B (zh) 酪醇在制备治疗脑胶质瘤的药物中的应用
US20030139373A1 (en) Method for cancer therapy
CN111773388B (zh) A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
Huang et al. A trial of outpatient chemotherapy for recurrent head and neck tumors
CN113786491A (zh) 一种含汉防己甲素、二氢槲皮素或槲皮素的抗肿瘤联用制剂
CN115381954B (zh) 一种用于治疗骨肉瘤的联合用药物
JP2014231518A (ja) 子宮腫瘍の治療用医薬の調製のための７−ｔ−ブトキシイミノメチルカンプトテシンの使用
KR20060036058A (ko) 결장직장암의 치료를 위한 혈관 손상 활성을 갖는 5ｆｕ,ｃｐｔ-11 또는 5-ｆｕ 및 ｃｐｔ-11과 함께 ｚｄ6126을포함하는 조성물
RU2279277C2 (ru) Лечение разделенными дозами агентов с сосудоразрушающей активностью
WO2002102373A1 (en) Method for administration of cancer therapeutic
JP2006518355A (ja) インドロピロロカルバゾール誘導体及び他の抗腫瘍薬を含む併用療法
HK40011479A (en) Method for administration of an anti-tumor agent

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080319

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080415

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080515

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110523

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4128872

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120523

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130523

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130523

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term